Top Markets
Coin of the day
Eli Lilly and Company Eli Lilly and Company

Eli Lilly and Company

LLY
Pozycja w akcjach #14
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to... Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Cena akcji
$1,133.97
Ostatnia synchronizacja: 2026-09-15
Kapitalizacja rynkowa
$1.068T
Zmiana (1 dzień)
-0.39%
Zmiana (1 rok)
48.29%
Kraj
US
Handel Eli Lilly and Company (LLY)

Kategoria

Historia dywidend dla Eli Lilly and Company (LLY)
Eli Lilly and Company (symbol giełdowy: LLY) wypłaciła łącznie 215 dywidend.
Suma wszystkich dywidend (skorygowana o podziały akcji): $72.49
Wskaźnik dywidendy (TTM): 0.0059
Wypłaty dywidend dla Eli Lilly and Company (LLY) od 1972 do 2026
Roczne wypłaty dywidend
Rok Dywidenda (skorygowana o podziały akcji) Zmień
2026 (TTM) $1.73 -71.17%
2025 $6.00 15.38%
2024 $5.20 15.04%
2023 $4.52 15.31%
2022 $3.92 15.29%
2021 $3.40 14.86%
2020 $2.96 14.73%
2019 $2.58 14.67%
2018 $2.25 8.17%
2017 $2.08 1.96%
2016 $2.04 2.00%
2015 $2.00 2.04%
2014 $1.96 0.00%
2013 $1.96 0.00%
2012 $1.96 0.00%
2011 $1.96 0.00%
2010 $1.96 0.00%
2009 $1.96 4.26%
2008 $1.88 10.59%
2007 $1.70 6.25%
2006 $1.60 5.26%
2005 $1.52 7.04%
2004 $1.42 5.97%
2003 $1.34 8.06%
2002 $1.24 10.71%
2001 $1.12 7.69%
2000 $1.04 13.04%
1999 $0.92 15.00%
1998 $0.8 8.11%
1997 $0.74 8.00%
1996 $0.6852 4.58%
1995 $0.6552 4.80%
1994 $0.6252 3.30%
1993 $0.6052 10.04%
1992 $0.55 10.00%
1991 $0.5 21.95%
1990 $0.41 21.55%
1989 $0.3373 17.28%
1988 $0.2876 15.04%
1987 $0.25 11.01%
1986 $0.2252 12.60%
1985 $0.2 7.58%
1984 $0.1859 8.21%
1983 $0.1718 5.79%
1982 $0.1624 13.09%
1981 $0.1436 4.51%
1980 $0.1374 12.81%
1979 $0.1218 18.14%
1978 $0.1031 16.10%
1977 $0.0888 13.55%
1976 $0.0782 13.66%
1975 $0.0688 13.53%
1974 $0.0606 22.67%
1973 $0.0494 116.67%
1972 $0.0228 0.00%
Lista wszystkich wypłat dywidend
Rok Dywidenda Zmień
2026 (TTM) $1.73 -71.17%
2025 $6.00 15.38%
2024 $5.20 15.04%
2023 $4.52 15.31%
2022 $3.92 15.29%
2021 $3.40 14.86%
2020 $2.96 14.73%
2019 $2.58 14.67%
2018 $2.25 8.17%
2017 $2.08 1.96%
2016 $2.04 2.00%
2015 $2.00 2.04%
2014 $1.96 0.00%
2013 $1.96 0.00%
2012 $1.96 0.00%
2011 $1.96 0.00%
2010 $1.96 0.00%
2009 $1.96 4.26%
2008 $1.88 10.59%
2007 $1.70 6.25%
2006 $1.60 5.26%
2005 $1.52 7.04%
2004 $1.42 5.97%
2003 $1.34 8.06%
2002 $1.24 10.71%
2001 $1.12 7.69%
2000 $1.04 13.04%
1999 $0.92 15.00%
1998 $0.8 -37.50%
1997 $1.28 -6.57%
1996 $1.37 -47.71%
1995 $2.62 4.80%
1994 $2.50 3.31%
1993 $2.42 10.00%
1992 $2.20 10.00%
1991 $2.00 21.95%
1990 $1.64 -2.73%
1989 $1.69 -26.70%
1988 $2.30 15.00%
1987 $2.00 11.11%
1986 $1.80 -43.75%
1985 $3.20 7.56%
1984 $2.98 8.18%
1983 $2.75 5.77%
1982 $2.60 13.04%
1981 $2.30 4.55%
1980 $2.20 12.82%
1979 $1.95 18.18%
1978 $1.65 16.20%
1977 $1.42 13.60%
1976 $1.25 13.64%
1975 $1.10 13.40%
1974 $0.97 22.47%
1973 $0.792 117.58%
1972 $0.364 0.00%
Wypłaty dywidend firm podobnych lub konkurencyjnych
Firma Liczba wypłat dywidend Kraj
225.00%
US
53.00%
US
33.00%
CH
223.00%
US
29.00%
CH